MedTrace Logo

Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan

NCT07088471 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 334

Last updated 2026-04-13

No results posted yet for this study

Summary

Heart failure is an increasingly common condition that can have a significant impact on quality of life and reduce life expectancy. In recent decades, a number of drugs have been developed specifically for this condition. One such drug, called Sacubitril/valsartan (SV) has been shown to reduce hospitalizations and prolong life expectancy of patients with heart failure. It works by reversing some of the structural and functional changes to the heart that occur in heart failure. However, not all patients respond to the drug. Further research is needed to better understand the reasons for this and predict who will benefit most from the drug.

Left atrial strain is a relatively new measurement that can be obtained using ultrasound imaging of the heart, and it provides objective information about how one of the heart's four chambers is functioning. The investigators aim to assess the effect of SV therapy on left atrial strain in patients with heart failure. The investigator's objective is to understand whether abnormal left atrial strain or changes in left atrial strain help predict response to SV therapy.

Conditions

  • Heart Failure and Reduced Ejection Fraction

Interventions

DRUG

Sacubtril/Valsartan

Angiotensin-receptor blocker and neprilysin inhibitor therapy

Sponsors & Collaborators

  • Connolly Hospital Blanchardstown

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-05-01
Completion
2025-08-01

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07088471 on ClinicalTrials.gov